Recombinant Toxic and Allergenic Proteins and cDNA: Advancements in Diagnosis and Vaccine Application

Products

Recombinant Toxic and Allergenic Proteins and cDNA

Recombinant toxic and allergenic proteins and cDNA are essential components for the development of new diagnostics and vaccines. These proteins and cDNA are synthetically produced using genetic engineering techniques and can be used to produce highly specific and sensitive diagnostic tools and vaccines.

Toxic proteins and allergenic proteins are known to cause serious health problems in humans and animals, such as allergies, autoimmune diseases, and toxicity. Thus, the ability to produce recombinant forms of these proteins can have significant benefits for both diagnosis and treatment.

In the diagnosis of diseases caused by toxic and allergenic proteins, recombinant proteins and cDNA are commonly used to develop assays for detecting these proteins in patients. These assays can be highly sensitive, specific, and rapid, which allows for early detection and treatment of the diseases. Moreover, these assays can also be used for disease monitoring and to evaluate the efficacy of therapies.

On the other hand, recombinant toxic and allergenic proteins can be used to develop vaccines for preventing the diseases caused by these proteins. Vaccines made from recombinant proteins and cDNA can induce a specific immune response that protects against the harmful effects of the proteins. These vaccines can be used to prevent a wide range of diseases, such as allergic reactions, autoimmune diseases, and toxicity.

Furthermore, the use of recombinant proteins and cDNA has significant advantages over traditional methods of producing vaccines. They are safer, more precise, and can be produced on a larger scale at a lower cost. This makes them a viable option for the development of vaccines against diseases caused by toxic and allergenic proteins.

Recombinant toxic and allergenic proteins and cDNA are useful tools for creating new vaccines and diagnostics, which can greatly benefit human and animal health by providing novel ways to prevent and treat a variety of diseases. These proteins and cDNA have become increasingly popular in both research and therapeutic settings. However, achieving successful expression of recombinant proteins in different systems requires optimization of several factors such as codon preference, RNA structure, and GC content. Bioclone has developed a technology platform that has created over 6,000 codon-optimized cDNA clones, which are readily available for producing recombinant proteins. Bioclone offers a wide selection of recombinant antigens and codon-optimized cDNA derived from various toxin sources.

cDNA and recombinant antigen

Codon-optimized cDNA is cloned into E. coli expression vector with 6x His-tag at N-terminus and ready-to-use for recombinant protein production.
Recombinant protein applications: Western Blot may be used for other applications determined by the user.
Protein Purity: >90%, as determined by SDS-PAGE under reducing conditions.
Protein Activity: N/A
Protein Tag: Contains A 6x histidine tag.
Protein Formulation: Liquid
Source: Produced from E. coli